Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1960 1
1980 1
1986 1
1987 1
1988 1
1989 1
1990 1
1991 2
1992 3
1993 2
1994 2
1995 2
1996 2
1997 1
1998 4
1999 5
2000 2
2001 4
2002 3
2003 8
2004 6
2005 6
2006 12
2007 9
2008 15
2009 10
2010 17
2011 10
2012 10
2013 10
2014 12
2015 6
2016 14
2017 12
2018 9
2019 11
2020 3
Text availability
Article attribute
Article type
Publication date

Search Results

206 results
Results by year
Filters applied: . Clear all
Page 1
Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis.
Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Lédinghen V, Kumar M, Lupsor-Platon M, Han KH, Cardoso AC, Ferraioli G, Chan WK, Wong VW, Myers RP, Chayama K, Friedrich-Rust M, Beaugrand M, Shen F, Hiriart JB, Sarin SK, Badea R, Jung KS, Marcellin P, Filice C, Mahadeva S, Wong GL, Crotty P, Masaki K, Bojunga J, Bedossa P, Keim V, Wiegand J. Karlas T, et al. Among authors: Wiegand J. J Hepatol. 2017 May;66(5):1022-1030. doi: 10.1016/j.jhep.2016.12.022. Epub 2016 Dec 28. J Hepatol. 2017. PMID: 28039099
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity.
Khan S, Zhang X, Lv D, Zhang Q, He Y, Zhang P, Liu X, Thummuri D, Yuan Y, Wiegand JS, Pei J, Zhang W, Sharma A, McCurdy CR, Kuruvilla VM, Baran N, Ferrando AA, Kim YM, Rogojina A, Houghton PJ, Huang G, Hromas R, Konopleva M, Zheng G, Zhou D. Khan S, et al. Among authors: Wiegand JS. Nat Med. 2019 Dec;25(12):1938-1947. doi: 10.1038/s41591-019-0668-z. Epub 2019 Dec 2. Nat Med. 2019. PMID: 31792461
Iberogast-Induced Acute Liver Failure-Reexposure and In Vitro Assay Support Causality.
Gerhardt F, Benesic A, Tillmann HL, Rademacher S, Wittekind C, Gerbes AL, Henker R, Berg T, Maidhof HP, Trauer H, Wiegand J. Gerhardt F, et al. Among authors: Wiegand J. Am J Gastroenterol. 2019 Aug;114(8):1358-1359. doi: 10.14309/ajg.0000000000000300. Am J Gastroenterol. 2019. PMID: 31246695 No abstract available.
Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement.
Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Lédinghen V, Kumar M, Lupsor-Platon M, Han KH, Cardoso AC, Ferraioli G, Chan WK, Wong VW, Myers RP, Chayama K, Friedrich-Rust M, Beaugrand M, Shen F, Hiriart JB, Sarin SK, Badea R, Lee HW, Marcellin P, Filice C, Mahadeva S, Wong GL, Crotty P, Masaki K, Bojunga J, Bedossa P, Keim V, Wiegand J. Karlas T, et al. Among authors: Wiegand J. Aliment Pharmacol Ther. 2018 Apr;47(7):989-1000. doi: 10.1111/apt.14529. Epub 2018 Feb 15. Aliment Pharmacol Ther. 2018. PMID: 29446106 Free article.
Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial.
Traussnigg S, Schattenberg JM, Demir M, Wiegand J, Geier A, Teuber G, Hofmann WP, Kremer AE, Spreda F, Kluwe J, Petersen J, Boettler T, Rainer F, Halilbasic E, Greinwald R, Pröls M, Manns MP, Fickert P, Trauner M; Austrian/German NAFLD-norUDCA study group. Traussnigg S, et al. Among authors: Wiegand J. Lancet Gastroenterol Hepatol. 2019 Oct;4(10):781-793. doi: 10.1016/S2468-1253(19)30184-0. Epub 2019 Jul 22. Lancet Gastroenterol Hepatol. 2019. PMID: 31345778
[Do NAFLD-patients require HCC screening?].
Karlas T, Wiegand J, Petroff D. Karlas T, et al. Among authors: Wiegand J. Z Gastroenterol. 2019 Feb;57(2):160-161. doi: 10.1055/a-0825-7739. Epub 2019 Feb 12. Z Gastroenterol. 2019. PMID: 30754062 German. No abstract available.
Therapy of Liver Abscesses.
Lübbert C, Wiegand J, Karlas T. Lübbert C, et al. Among authors: Wiegand J. Viszeralmedizin. 2014 Oct;30(5):334-41. doi: 10.1159/000366579. Viszeralmedizin. 2014. PMID: 26287275 Free PMC article. Review.
206 results
Jump to page
Feedback